Rigel Pharmaceuticals, Inc. (RIGL) — Stock Score Summary

Rigel Pharmaceuticals, Inc. (RIGL) has a MoatMap StockRank of 87/100 based on Quality (80/100), Value (71/100), and Momentum (21/100) factor scores. The current signal is STRONG BUY. Rigel Pharmaceuticals is a small-cap commercial-stage biotech company. It lacks the scale, diversified pipeline, and structural moat required for a concentrated global equity fund, and does not align with our CDMO or manufacturing themes.

Rigel Pharmaceuticals, Inc. is a commercial-stage biotechnology company dedicated to the discovery, development, and provision of novel small molecule drugs for serious diseases. Its approved product, TAVALISSE, is used to treat chronic immune thrombocytopenia, showcasing its expertise in immunology. Rigel maintains a competitive edge through its proprietary R&D platform and pipeline targeting various immunological and oncological conditions.

Key Financial Metrics

Price$30.72
Market Cap$556M
P/E (TTM)1.57
P/E (Forward)6.60
Price/Book1.40
Return on Equity174.1%
Return on Invested Capital31.2%
Debt/Equity11.43
Gross Margin81.2%
Operating Margin20.2%
Revenue Growth10.3%
Free Cash Flow$79M

Rigel Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Rigel Pharmaceuticals, Inc.’s (RIGL) StockRank?
MoatMap’s StockRank for Rigel Pharmaceuticals, Inc. (RIGL) is 87/100, with a Strong Buy signal. It is a composite of Quality (80), Value (71), and Momentum (21) factor ranks across MoatMap’s 19,000+ stock universe.
Does Rigel Pharmaceuticals, Inc. have an economic moat?
Rigel Pharmaceuticals, Inc. (RIGL) has a Quality factor score of 80/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Rigel Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Rigel Pharmaceuticals, Inc. (RIGL) is Strong Buy, based on a StockRank of 87/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Rigel Pharmaceuticals, Inc. in?
Rigel Pharmaceuticals, Inc. (RIGL) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksRIGL deep dive reportAI ChampionsHow we score stocksSense-check another stock